Los Angeles Capital Management LLC Precision Biosciences Inc Transaction History

Los Angeles Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$1.15 - $3.34 $199,865 - $580,478	-173,796 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$2.96 - $7.76 $362,617 - $950,646	122,506 Added 238.85%	173,796 $535,000
Q4 2021 Feb 03, 2022	SELL	$7.4 - $11.66 $25,789 - $40,635	-3,485 Reduced 6.36%	51,290 $380,000
Q3 2021 Nov 08, 2021	SELL	$9.18 - $14.15 $22,399 - $34,526	-2,440 Reduced 4.26%	54,775 $632,000
Q2 2021 Aug 05, 2021	SELL	$8.07 - $12.52 $85,283 - $132,311	-10,568 Reduced 15.59%	57,215 $716,000
Q1 2021 May 05, 2021	SELL	$8.57 - $15.79 $124,950 - $230,218	-14,580 Reduced 17.7%	67,783 $701,000
Q4 2020 Feb 04, 2021	BUY	$5.98 - $12.47 $157,812 - $329,083	26,390 Added 47.15%	82,363 $687,000
Q3 2020 Nov 02, 2020	BUY	$4.65 - $8.73 $27,807 - $52,205	5,980 Added 11.96%	55,973 $345,000
Q2 2020 Aug 05, 2020	BUY	$4.66 - $8.7 $121,160 - $226,199	26,000 Added 108.36%	49,993 $416,000
Q1 2020 May 04, 2020	BUY	$5.05 - $15.01 $121,164 - $360,134	23,993 New	23,993 $145,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $553M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.